Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience.

Danilo De NovellisRaffaele FontanaSalvatore PalmieriRoberta Della PepaMaria Di PernaGiusy CetaniDaniela EspositoAngela AmendolaGiuseppe Delle CaveBianca SerioDenise MoriniMichela RizzoLaura MettivierFabio TrastulliStefano RoccoAnastasia PaganoSerafina BarbatoAldo LeoneMartina La MagnaRosario BiancoGabriella RascatoAngela CarobeneBianca CuffaMarialuigia IannalfoValentina GiudiceGino SvaneraMario AnnunziataMichele PizzutiFerdinando FrigeriCatello CalifanoFelicetto FerraraFabrizio PaneCarmine Selleri

Published in: Targeted oncology (2023)

Subcutaneous daratumumab was safe in a real-life setting including patients with severe renal failure and advanced disease. However, further studies on larger and prospective cohorts are required to confirm our real-life observations.

Keyphrases

monoclonal antibody
multiple myeloma
single cell
cell therapy
early onset
cross sectional
case control
stem cells
mesenchymal stem cells